LyP-1 binds directly to the lymphatic vessels in certain tumors and its distinctiveness as a targeting peptide rests squarely on its potential to induce apoptosis upon cell binding as well as its dual cellular uptake by tumor and lymphatic endothelial cells. Here, PTPN22 is linked to neoplasm.